Managing Treatment Related Side Effects - CML
... List of drugs causing QTc prolongation is extensive: anti-arrhythmics, ...
... List of drugs causing QTc prolongation is extensive: anti-arrhythmics, ...
Paradoxical Vocal Fold Motion (PVFM)
... Phonatory: Speech vs non-speech breathing Behavioral: Psychological/Psychiatric/Habituation Digestive: Gastroesophageal disorder Rhinoallergenic: Pollution/Irritants ...
... Phonatory: Speech vs non-speech breathing Behavioral: Psychological/Psychiatric/Habituation Digestive: Gastroesophageal disorder Rhinoallergenic: Pollution/Irritants ...
CT and MR of MELAS Syndrome
... infarcts in two. Of these patients, two had strokelike episodes but neither was short nor had lactic acidosis, thereby not meeting all the major criteria for the diagnosis of MELAS syndrome. Most patients with MELAS syndrome are affected in youth or early adulthood, but the course of lesion appearan ...
... infarcts in two. Of these patients, two had strokelike episodes but neither was short nor had lactic acidosis, thereby not meeting all the major criteria for the diagnosis of MELAS syndrome. Most patients with MELAS syndrome are affected in youth or early adulthood, but the course of lesion appearan ...
Management of Secondary Lymphoedema
... capacity of the lymphatic circulation. The condition usually affects the limb(s) although it can also involve the trunk, breast, head and neck or genital area. Secondary lymphoedema is acquired following surgery, radiotherapy, trauma or other damage to the lymphatic system following treatment for ca ...
... capacity of the lymphatic circulation. The condition usually affects the limb(s) although it can also involve the trunk, breast, head and neck or genital area. Secondary lymphoedema is acquired following surgery, radiotherapy, trauma or other damage to the lymphatic system following treatment for ca ...
Journal of IMAB Annual Proceeding (Scientific Papers) 2010
... Streinu-Cercel A, Antonica D, Draganescu A., Gubavu C., Gliga S. National Institute of Infectious Diseases “Matei Bals”, Bucharest, Romania Without local epidemiology of antimicrobial susceptibility data, the first line syndromes therapy could be less adequate and could involve a greater risk for ba ...
... Streinu-Cercel A, Antonica D, Draganescu A., Gubavu C., Gliga S. National Institute of Infectious Diseases “Matei Bals”, Bucharest, Romania Without local epidemiology of antimicrobial susceptibility data, the first line syndromes therapy could be less adequate and could involve a greater risk for ba ...
Comprehensive Management of Patients Presenting to the
... the clinic by a single rhinologist (D.L.) for sinus pressure, headache, fullness, or pain (study symptoms) between September 2010 and April 2012 was conducted. Final diagnosis, interventions, and outcomes were noted. Positive outcome was noted by one of three criteria: 1) subjective report of improv ...
... the clinic by a single rhinologist (D.L.) for sinus pressure, headache, fullness, or pain (study symptoms) between September 2010 and April 2012 was conducted. Final diagnosis, interventions, and outcomes were noted. Positive outcome was noted by one of three criteria: 1) subjective report of improv ...
PPT - Larry Smarr - California Institute for Telecommunications and
... Next Decade Will See New Microbiome “Gardening Tools” ...
... Next Decade Will See New Microbiome “Gardening Tools” ...
Number Needed to Treat
... timolol to PREVENT varices in patients with diagnosed cirrhosis. • Remember that this is different from patients who have ALREADY had an upper GI bleed from varices secondary to cirrhosis. Those patients should get a beta blocker. ...
... timolol to PREVENT varices in patients with diagnosed cirrhosis. • Remember that this is different from patients who have ALREADY had an upper GI bleed from varices secondary to cirrhosis. Those patients should get a beta blocker. ...
Treatment of Resistant Hypertension in the Patient With Chronic
... personalized education focused on improving health literacy and promoting a better understanding of risks related to poorly controlled HTN. Another significant issue leading to pseudoresistance involves errors in measurement of blood pressure. One of the most common causes of blood pressure assessmen ...
... personalized education focused on improving health literacy and promoting a better understanding of risks related to poorly controlled HTN. Another significant issue leading to pseudoresistance involves errors in measurement of blood pressure. One of the most common causes of blood pressure assessmen ...
PEPTIC ULCER AND NON ULCER DYSPEPSIA
... • Treatment of PUD consists of healing the ulcer and prevention of complications. All plans should include appropriate management of PUD risk factors. • discontinue smoking; offered stress management programs and counseled to avoid NSAIDs, aspirin, and alcohol abuse. • Management of patients with P ...
... • Treatment of PUD consists of healing the ulcer and prevention of complications. All plans should include appropriate management of PUD risk factors. • discontinue smoking; offered stress management programs and counseled to avoid NSAIDs, aspirin, and alcohol abuse. • Management of patients with P ...
06- Asthma
... responsible for production of cysteinyl leukotrienes. Leukotrienes C4, D4, and E4 are released during inflammatory processes in the lung and produce bronchospasm, mucus secretion, microvascular permeability, and airway edema. ...
... responsible for production of cysteinyl leukotrienes. Leukotrienes C4, D4, and E4 are released during inflammatory processes in the lung and produce bronchospasm, mucus secretion, microvascular permeability, and airway edema. ...
Clinical findings associated with propranolol and fenofibrate on
... Additionally, after 8 weeks of treatment, there was statistically significant difference between two treatments for SBP and DBP, whereas the difference of blood lipid (including TC and TG) was not statistically significant (all P>0.05), as shown in Table 2. Discussion Acute CSC is characterized by m ...
... Additionally, after 8 weeks of treatment, there was statistically significant difference between two treatments for SBP and DBP, whereas the difference of blood lipid (including TC and TG) was not statistically significant (all P>0.05), as shown in Table 2. Discussion Acute CSC is characterized by m ...
Noonan syndrome and Turner syndrome patients respond similarly
... and visit year; adjusted for age at treatment start, HSDS at baseline and average GH dose Disease-specific ΔHSDS (Ranke) from baseline showed a significant increase from baseline per visit-year for each indication (NS: years 1–2 and years 2–3 [P < 0.0001], and years 3–4 [P = 0.0271]; ...
... and visit year; adjusted for age at treatment start, HSDS at baseline and average GH dose Disease-specific ΔHSDS (Ranke) from baseline showed a significant increase from baseline per visit-year for each indication (NS: years 1–2 and years 2–3 [P < 0.0001], and years 3–4 [P = 0.0271]; ...
Now Indicated as a Single Agent for the Treatment of B
... -----------------------------INDICATIONS AND USAGE--------------------------Campath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) (1). --------------------------DOSAGE AND ADMINISTRATION-----------------------• Admi ...
... -----------------------------INDICATIONS AND USAGE--------------------------Campath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) (1). --------------------------DOSAGE AND ADMINISTRATION-----------------------• Admi ...
Tuberculosis and opportunistic infections
... and of RA patients. For example, among RA patients treated with infliximab in the USA, the prevalence of TB has been estimated to range from 24.4/ 100,000 (based on cases reported to the FDA as of May 2001; reference 37) to 52.5/ 100,000 (based upon a survey of RA patients from January 2000 to June ...
... and of RA patients. For example, among RA patients treated with infliximab in the USA, the prevalence of TB has been estimated to range from 24.4/ 100,000 (based on cases reported to the FDA as of May 2001; reference 37) to 52.5/ 100,000 (based upon a survey of RA patients from January 2000 to June ...
Accepted version
... found in a latent state after acute infection and have previously been associated with other autoimmune diseases 11,21,22. On the other hand, measles can rarely cause subacute sclerosing panencephalitis, a progressive infection caused by persistent mutated virus, but is part of the routine infant va ...
... found in a latent state after acute infection and have previously been associated with other autoimmune diseases 11,21,22. On the other hand, measles can rarely cause subacute sclerosing panencephalitis, a progressive infection caused by persistent mutated virus, but is part of the routine infant va ...
Full Article - Medical Ultrasonography Journal
... with high doses of antiparasitic drugs such as Albendazole and Mebendazole. Among the factors that influence the outcome of the chemotherapy are chemotherapy drug type, the age of the cyst, the patient’s age and the location and morphological characteristics of the cyst [1]. Albendazole is the first ...
... with high doses of antiparasitic drugs such as Albendazole and Mebendazole. Among the factors that influence the outcome of the chemotherapy are chemotherapy drug type, the age of the cyst, the patient’s age and the location and morphological characteristics of the cyst [1]. Albendazole is the first ...
Smoking and Prognostic Factors in an Observational Setting in
... the effect of smoking on survival in advanced NSCLC treated with chemotherapy. Furthermore, limited data is available on the effect of smoking on chemotherapy toxicity. Considering the high incidence of advanced stage NSCLC and the common use of chemotherapy in these patients, these questions appear ...
... the effect of smoking on survival in advanced NSCLC treated with chemotherapy. Furthermore, limited data is available on the effect of smoking on chemotherapy toxicity. Considering the high incidence of advanced stage NSCLC and the common use of chemotherapy in these patients, these questions appear ...
Pamidronate disodium belongs to a group of medicines called
... glomerular filtration rate (GFR). By controlling hypercalcaemia, pamidronate disodium improves GFR and lowers elevated serum creatinine levels in most patients. In two clinical trials with a total of 82 cancer patients who had hypercalcaemia, Pamidronate was administered as a single 24-hour intraven ...
... glomerular filtration rate (GFR). By controlling hypercalcaemia, pamidronate disodium improves GFR and lowers elevated serum creatinine levels in most patients. In two clinical trials with a total of 82 cancer patients who had hypercalcaemia, Pamidronate was administered as a single 24-hour intraven ...
Psychiatric treatment considerations with direct
... boceprevir and telaprevir and ritonavir-boosted HIV protease inhibitors, with significant reductions in exposures of HCV agents and HIV protease inhibitors; therefore, telaprevir should not be coadministered with ritonavirboosted darunavir, fosamprenavir, or lopinavir [18] and boceprevir is not reco ...
... boceprevir and telaprevir and ritonavir-boosted HIV protease inhibitors, with significant reductions in exposures of HCV agents and HIV protease inhibitors; therefore, telaprevir should not be coadministered with ritonavirboosted darunavir, fosamprenavir, or lopinavir [18] and boceprevir is not reco ...
Appropriate Antibiotic Use for Patients With Urinary Tract Infections
... model with a random intercept and all other variables fixed. To investigate a possible relationship between performance on the total set of QIs and LOS, we first calculated in each patient the proportion of appropriate antibiotic use, defined as the patient’s QI sum score divided by the number of QIs t ...
... model with a random intercept and all other variables fixed. To investigate a possible relationship between performance on the total set of QIs and LOS, we first calculated in each patient the proportion of appropriate antibiotic use, defined as the patient’s QI sum score divided by the number of QIs t ...
united states securities and exchange commission - corporate
... On June 4, 2016, ARIAD Pharmaceuticals, Inc. (the “Company”) issued the first of three press releases announcing data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. This press release detailed updated clinical data on the Company’s investigati ...
... On June 4, 2016, ARIAD Pharmaceuticals, Inc. (the “Company”) issued the first of three press releases announcing data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. This press release detailed updated clinical data on the Company’s investigati ...
KADCYLA Prescribing Information
... Closely monitor the infusion site for possible subcutaneous infiltration during drug administration [see Warnings and Precautions (5.10)]. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for f ...
... Closely monitor the infusion site for possible subcutaneous infiltration during drug administration [see Warnings and Precautions (5.10)]. First infusion: Administer infusion over 90 minutes. Patients should be observed during the infusion and for at least 90 minutes following the initial dose for f ...
Data Sheet
... Repeat courses of leuprorelin acetate or any other GnRH agonist following an initial six month course of therapy should not be considered without assessment of the risk of developing osteoporosis. No data are available for women receiving the treatment for a longer period of time. Central Precociou ...
... Repeat courses of leuprorelin acetate or any other GnRH agonist following an initial six month course of therapy should not be considered without assessment of the risk of developing osteoporosis. No data are available for women receiving the treatment for a longer period of time. Central Precociou ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.